4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nanobiotix S.A. (NBTX) operates in the Biotechnology industry and is headquartered in Paris, France with about 100 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NBTX reported $30M in revenue and ($24M) in net income.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Interactive charts & full statements → Open the NBTX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $30M | ($12M) | $30M | $0M | — |
| Operating Income (EBIT) | ($11M) | ($68M) | ($27M) | ($47M) | — |
| Net Income | ($24M) | ($68M) | ($40M) | ($57M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $68M | $67M | $94M | $60M | — |
| Total Liabilities | $152M | $133M | $96M | $87M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NBTX viewer.
About TickerBase · Data methodology & sources